doi: 10.1016/j.pharmthera.2006.11.007
It is administered as a once-weekly injection and is frequently compared to other GLP-1 medications such as Ozempic and Mounjaro, which serve similar therapeutic purposes but differ in dosing and reported side effect profiles
Aim for 70 to 120 grams of protein daily, distributed across your meals
On your first day, the injection will typically be administered by a trial nurse or clinician in a supervised clinical setting
[2] [3] It belongs to a novel class of agents known as triple hormone receptor agonists , meaning it simultaneously activates three distinct receptors involved in appetite regulation and energy metabolism: GLP-1 (glucagon-like peptide-1) receptor reduces appetite and slows gastric emptying GIP (glucose-dependent insulinotropic polypeptide) receptor enhances insulin secretion and, based on preclinical and early clinical evidence, may contribute to improved fat metabolism Glucagon receptor preclinical and early clinical data suggest activation of this receptor may increase energy expenditure and promote fat breakdown (lipolysis), though the precise contribution in humans is still being characterised This triple-action mechanism distinguishes retatrutide from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 receptor agonist)
Amyloid deposition as the central event in the aetiology of Alzheimers disease
